

Magellan Biologics and the Portugal 2020 Program

We are grateful towards the Portugal 2020 program, the Program Norte 2020 and the European Union for providing significant financial support for the establishment of a functional laboratory at i3S.



Project name	Innovation and Entrepreneurship
Project code	18693 (Norte-02-0651-FEDER-018693)
Main goal	To increase the competitiveness of small and medium-sized enterprises
Intervention area	North
Beneficiary entity	Magellan - Biologics & Consulting, Lda
Approval date	06-12-2016
Start date	01-05-2016
Conclusion date	07-09-2018
Total eligible cost	384 277.20 €
EU financial support (FEDER)	288 207.90 €

Activities

- R&D in pharmaceutical and general biotechnology based on recombinant DNA
- Expression of recombinant and non-recombinant biologics for R&D
- Development of innovative reagents and provisioning of services for R&D of biopharmaceuticals
- Providing advisory assistance to individuals and companies that wish to develop protein and virus-based biologics for pharmaceutical uses (technology, patent landscape, regulatory).

Goals

- Development of innovative approaches for protein expression with cultured animal cells
- Facilitation of R&D activities in industry and academia in need of technologies for expression of biologics
- Expansion of the company's portfolio of life-science products
- Consolidate and expand the company's presence in international markets
- Providing a network of know-how providers in cutting edge technologies for biologics generation and production